We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GPCR Structure Therapeutics Inc

-0.77 (-1.25%)
After Hours
Last Updated: 15:01:50
Delayed by 15 minutes


Draw Mode:

Volume 479,189
Bid Price 60.00
Ask Price 61.94
News -
Share Name Share Symbol Market Stock Type
Structure Therapeutics Inc GPCR NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
-0.77 -1.25% 60.73 15:01:50
Open Price Low Price High Price Close Price Previous Close
62.90 60.38 63.30 60.73 61.50
Trades Shares Traded VWAP Financial Volume Average Volume
6,752 479,189  61.57  29,502,202 -
Last Trade Type Quantity Price Currency
15:26:47 1  61.94 USD

Structure Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 0.00 - 0 -52.84M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Structure Therapeutics

Date Time Source Heading
11/29/202323:15Edgar (US Regulatory)Form EFFECT - Notice of Effectiveness
11/17/202316:25Edgar (US Regulatory)Form S-1 - General form for registration of securities under..
11/17/202315:55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/17/202315:51Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
11/16/202316:13Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
11/14/202315:10GlobeNewswire Inc.Structure Therapeutics Reports Third Quarter 2023 Financial..
9/29/202306:50Edgar (US Regulatory)Form 8-K - Current report
9/29/202306:38Edgar (US Regulatory)Form 8-K - Current report
9/29/202306:32GlobeNewswire Inc.Structure Therapeutics Announces $300 Million Private..
9/29/202306:30GlobeNewswire Inc.Structure Therapeutics Announces Positive Results from Phase..
8/10/202315:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/202315:19Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No GPCR Message Board. Create One! See More Posts on GPCR Message Board See More Message Board Posts

GPCR Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Its initial focus is on G-protein-coupled receptors as a therapeutic target class. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor for the treatment of type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases. Specifically, it is advancing ANPA-0073, its biased agonist, targeting the apelin receptor. It is also developing LTSE-2578, an investigational oral small molecule LPA1R antagonist for the treatment of idiopathic pulmonary fibrosis.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |